Question 1

What is Dasatinib?

Accepted Answer

Dasatinib belongs to a class of medications known as tyrosine kinase inhibitors . It functions by targeting and interfering with the action of specific abnormal proteins that signal cells to multiply, which helps slow or stop the progression of certain conditions.

By inhibiting these signals, the medication helps manage the overproduction of specific cells. This targeted approach focuses on the molecular drivers of cell growth rather than affecting all rapidly dividing cells throughout the body.

Question 2

What is Dasatinib used for?

Accepted Answer

Dasatinib is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia .

Question 3

How does Dasatinib work?

Accepted Answer

How Dasatinib Works

Dasatinib is a type of medication known as a tyrosine kinase inhibitor. It works by identifying and blocking specific proteins, called kinases, that are found in cancer cells. These proteins act as signaling molecules that tell cells when to grow and divide. In certain cancers, these proteins are overactive, leading to the uncontrolled growth of abnormal cells.

Blocking Abnormal Growth Signals

In patients with certain types of leukemia, such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), an abnormal genetic change creates a protein called BCR-ABL. This protein sends constant signals for the body to produce excessive amounts of white blood cells. Dasatinib binds to this protein and blocks its activity, which helps stop the production of these cancerous cells.

Targeting Multiple Pathways

Dasatinib is considered a multi-kinase inhibitor because it targets several different proteins involved in cancer progression. These include:

BCR-ABL

SRC family kinases

c-KIT

Ephrin (EPH) receptor kinases

Platelet-derived growth factor receptor beta (PDGFR&beta;)

By interfering with these multiple signaling pathways, the medication helps to slow the growth of the cancer and may help the bone marrow return to normal function.

Question 4

What are the brand names for Dasatinib?

Accepted Answer

Dasatinib is sold under the brand name Sprycel .

Question 5

What are the active ingredients in Dasatinib?

Accepted Answer

The active ingredient in Dasatinib is dasatinib .

Question 6

What are the side effects of Dasatinib?

Accepted Answer

Common side effects of Dasatinib may include:

diarrhea

fatigue

headache

and others

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Dasatinib?

Accepted Answer

Dasatinib belongs to the tyrosine kinase inhibitor drug class.

Question 8

What is the dosage of Dasatinib and how do I take it?

Accepted Answer

Dasatinib is available as tablets and an oral suspension. It is usually taken once a day, either in the morning or evening, though some conditions may require twice-daily dosing. It can be taken with or without food. It is important to take this medication at the same time each day to maintain a consistent level in the body.

When taking the tablets:

Swallow the tablets whole.

Do not crush, cut, or chew the tablets.

When taking the oral suspension:

Shake the bottle well for several seconds before measuring a dose.

Use the specific oral syringe provided with the medication to ensure the correct amount is measured.

Do not mix the suspension with water or food.

If a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. Do not take extra medicine to make up for a missed dose.

Question 9

Is Dasatinib safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Dasatinib can cause harm to a fetus when taken during pregnancy. Clinical reports have documented instances of birth defects and other complications in infants exposed to the medication before birth. Individuals who are able to become pregnant should undergo a pregnancy test before starting this medication to confirm they are not pregnant.

Effective contraception is recommended for both men and women during treatment. Women should continue using birth control for at least 30 days after their last dose. Men with partners who can become pregnant should also use effective contraception during treatment and for 30 days after the final dose. If pregnancy is suspected or occurs during treatment, a healthcare provider should be notified immediately.

Breastfeeding

It is currently unknown if dasatinib passes into human breast milk. Due to the risk of serious adverse reactions in a nursing child, breastfeeding is not recommended during treatment and for at least 2 weeks following the final dose. Patients should consult with their healthcare team to discuss the best way to feed their baby during this time.

Question 10

What forms and strengths does Dasatinib come in?

Accepted Answer

Dasatinib is available in the following form:

Oral Tablet: These are film-coated tablets intended to be swallowed whole.

This medication should not be crushed, cut, or chewed. It is currently only available as a tablet and does not come in liquid or injectable formulations.

Question 11

What is the FDA approval status of Dasatinib?

Accepted Answer

FDA Approval and Indications

Dasatinib was approved by the U.S. Food and Drug Administration (FDA) to treat certain forms of leukemia in adults and children. Its primary indications include:

Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.

Ph+ CML in chronic, accelerated, or blast phases for patients who no longer benefit from or cannot tolerate other treatments.

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in patients with resistance or intolerance to prior therapy.

In pediatric patients, it is approved for Ph+ CML in the chronic phase and for Ph+ ALL in combination with chemotherapy.

Safety Monitoring and Communications

The FDA monitors the safety profile of dasatinib through the FDA Adverse Event Reporting System (FAERS). In 2018, the FDA identified a potential signal of serious risk regarding pulmonary hypertension associated with the use of this drug. Labeling includes warnings for serious conditions such as myelosuppression, fluid retention, and cardiovascular events.

There is currently no Risk Evaluation and Mitigation Strategy (REMS) required for this medication. Generic versions of dasatinib have been approved by the FDA, providing alternatives to the brand-name version.

Question 12

What should I know about Dasatinib and fda?

Accepted Answer

The U.S. Food and Drug Administration (FDA) has approved dasatinib for the treatment of several conditions involving Philadelphia chromosome-positive (Ph+) cancers:

Chronic Myeloid Leukemia (CML): It is approved for adults with newly diagnosed Ph+ CML in the chronic phase. It is also used for adults with chronic, accelerated, or blast phase Ph+ CML who are resistant to or intolerant of other therapies.

Acute Lymphoblastic Leukemia (ALL): It is approved for adults with Ph+ ALL who have not responded to or cannot tolerate other treatments.

Pediatric Use: The FDA has approved dasatinib for children aged one year and older who have Ph+ CML in the chronic phase or newly diagnosed Ph+ ALL when used in combination with chemotherapy.

The FDA has identified several serious risks associated with dasatinib that require medical monitoring:

Myelosuppression: This medication can cause a severe decrease in blood cell counts, including platelets, red blood cells, and white blood cells.

Fluid Retention: Patients may experience significant fluid buildup, which can occur around the lungs, the heart, or in the abdomen.

Cardiovascular Concerns: There is a risk of heart-related issues, including heart failure and changes in heart rhythm, such as QT prolongation.

Pulmonary Arterial Hypertension: A rare but serious condition involving high blood pressure in the lung arteries has been reported in patients taking this drug.

Bleeding Events: Severe and sometimes fatal bleeding has occurred in patients treated with this medication.

The FDA also warns that dasatinib can cause harm to a developing fetus. It is recommended that individuals of reproductive potential use effective contraception during treatment and for a period after the final dose.

Dasatinib

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Fda Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?